Últimas noticias sobre Enzolytics (OTC:ENZC) Bolsa

Enzolytics Inc is a biotechnology company, whose products consist of multiple distinct drug development proprietary technologies: Immunotherapy, immune modulators, fully human monoclonal antibodies, and an artificial intelligence (AI) platform for health care developments. It has clinically tested anti-HIV therapeutics. Additionally, the Company has created a proprietary cell line that produces fully human monoclonal antibodies that target and neutralize HIV.

Enzolytics Inc

News

Offerings

OSUR

Orasure Technologies Files For Mixed Shelf Of Up To $300M

General

Equus Total Return Receives NYSE Notice Of Non-Compliance With Minimum Share Price Requirement

Deupirfenidone 825 mg TID slowed lung function decline in people with idiopathic pulmonary fibrosis (IPF) to the range expected of healthy older adults over 6 months; new, preliminary open-label extension data support durability of this treatment effect over at least 52 weeks
Deupirfenidone 825 mg TID demonstrated a statistically significant benefit compared to placebo in delaying IPF progression
Detailed safety analysis underscores favorable tolerability profile for deupirfenidone
PureTech plans to meet with FDA before end of Q3 2025, with the goal of initiating a Phase 3 trial by year-end
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpuretechhealth.com%2F&amp;esheet=54257865&amp;newsitemid=20250520345638&amp;lan=en-US&amp;anchor=PureTech+Health+plc&amp;index=1&amp;md5=d3c41ff08eb102e88d128b2fd110bddc">PureTech Health plc</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTC#NASDAQ">PRTC</a>, LSE: PRTC))) (&quot;PureTech&quot; or the &quot;Company&quot;), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, delivered a late-breaking, oral presentation at the 2025 American Thoracic Society (ATS) International Conference in San Francisco. The presentation provided further insights into the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fnews.puretechhealth.com%2Fnews-releases%2Fnews-release-details%2Fpuretechs-deupirfenidone-lyt-100-slowed-lung-function-decline&amp;esheet=54257865&amp;newsitemid=20250520345638&amp;lan=en-US&amp;anchor=successful+Phase+2b+ELEVATE+IPF+trial&amp;index=2&amp;md5=df2f852b2e4793a012c9f61e73a222f2">successful Phase 2b ELEVATE IPF trial</a> of deupirfenidone (LYT-100), highlighting the strength and durability of deupirfenidone&#39;s treatment effect through at least 52 weeks while maintaining favorable tolerability in patients living with idiopathic pulmonary fibrosis (IPF).

Biotech

PRTC

PureTech Presents Phase 2b Data For Deupirfenidone At ATS 2025, Showing Statistically Significant Slowing Of IPF Progression With Durable Effect Over 52 Weeks, Favorable Safety Profile, And Plans For FDA Meeting And Phase 3 Trial Launch By End Of 2025

Insider Trades

BDSX

Biodesix Form4 Filing Shows Jack Schuler Bought 4,723,239 Shares Of Stock At An Average Price Of $0.28/Share

Aon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) has outperformed the market over the past 15 years by 4.05% on an annualized basis producing an average annual return of 16.13%. Currently, Aon has a market capitalization of $78.26 billion. 
Buying $100 In AON: If an investor had bought $100 of AON stock 15 years ago, it would be worth $934.58 today based on a price of $362.43 for AON at the time of writing.
<h3>Aon's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747775712_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In Aon 15 Years Ago Would Be Worth This Much Today

Shares of Advanced Micro Devices Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) and NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) are moving higher in Tuesday&#8217;s after-hours session after Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk announced that the company expects to purchase &#8220;a lot&#8221; of GPUs <a href="https://www.benzinga.com/news/25/04/44725803/musks-xai-aims-for-1-million-gpus-in-memphis-but-can-the-citys-grid-handle-a-27b-ai-power-surge">from the chip companies</a>.
What Happened: In an interview aired on CNBC&#8217;s &#8220;Closing Bell: Overtime,&#8221; Musk laid out a vision for the future that includes millions of fully autonomous robotaxi vehicles and Optimus bots. When asked how many GPUs the company will need to make that vision a reality, Musk said &#8220;quite a few.&#8221;
&#8220;We expect to still buy a lot of GPUs from Nvidia, some from AMD, and maybe from others,&#8221; Musk said. &#8220;As long as Nvidia is better than what we make, we&#8217;ll keep buying from Nvidia.&#8221;
Musk told CNBC that his vision is less than five years away. He also noted that his AI company xAI plans to continue buying GPUs from Nvidia. He highlighted the AI company&#8217;s training cluster, which he believes is the most powerful in the world right now, with over 200,000 GPUs at its facility in Memphis. 
Musk also told CNBC that xAI is in the process of building a second location that will feature one million Nvidia Blackwell GPUs, expected to be completed in the next six to nine months.
&#8220;It will be the first gigawatt-class training cluster in the world,&#8221; he said.
In after-hours at the time of publication on Tuesday, <a href="http://benzinga.com/quote/AMD">AMD shares</a> were up 0.77% at $114.38 and <a href="http://benzinga.com/quote/nvda">Nvidia shares</a> were narrowly higher, up 0.11% at $134.52 at last check, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: courtesy of Nvidia.

After-Hours Center

Movers

Tech

NVDA

TSLA

AMD, Nvidia Shares Jump After Musk Highlights xAI's GPU Needs: 'We Expect To Still Buy A Lot'

<a href="https://www.wsj.com/articles/wolfspeed-prepares-to-file-for-bankruptcy-within-weeks-7bd98040">https://www.wsj.com/articles/wolfspeed-prepares-to-file-for-bankruptcy-within-weeks-7bd98040</a>

WOLF

' Wolfspeed Prepares to File for Bankruptcy Within Weeks'- WSJ

<h3>Gainers</h3>
<ul>
<li>Big 5 Sporting Goods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGFV#NASDAQ">BGFV</a>) shares moved upwards by 8.3% to $1.31 during Tuesday's after-market session. The company's market cap stands at $29.9 million. </li>
<li>Smith Douglas Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDHC#NYSE">SDHC</a>) shares moved upwards by 6.34% to $18.1. The market value of their outstanding shares is at $930.8 million. The company's, Q1 earnings came out 4 days ago. </li>
<li>XWELL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XWEL#NASDAQ">XWEL</a>) stock rose 5.8% to $0.97. The market value of their outstanding shares is at $5.1 million. As per the news, the Q1 earnings report came out today. </li>
<li>Toll Brothers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) shares moved upwards by 5.63% to $110.4. The company's market cap stands at $11.0 billion. The company's, Q2 earnings came out today. </li>
<li>Lulus Fashion Lounge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVLU#NASDAQ">LVLU</a>) shares moved upwards by 4.98% to $0.39. The company's market cap stands at $16.7 million. As per the press release, Q1 earnings came out 4 days ago. </li>
<li>Soho House (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHCO#NYSE">SHCO</a>) shares rose 4.81% to $6.75. The market value of their outstanding shares is at $1.3 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Neo-Concept International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCI#NASDAQ">NCI</a>) shares fell 17.6% to $0.35 during Tuesday's after-market session. The company's market cap stands at $7.1 million. </li>
<li>Outdoor Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWW#NASDAQ">POWW</a>) shares fell 12.16% to $1.59. The market value of their outstanding shares is at $188.8 million. </li>
<li>Carter's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRI#NYSE">CRI</a>) shares decreased by 10.26% to $33.0. The company's market cap stands at $1.2 billion. </li>
<li>Mingteng International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEN#NASDAQ">MTEN</a>) shares fell 9.23% to $12.3. The market value of their outstanding shares is at $84.1 million. </li>
<li>MEDIROM Healthcare Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRM#NASDAQ">MRM</a>) stock declined by 8.47% to $1.19. The company's market cap stands at $9.4 million. As per the news, the FY earnings report came out today. </li>
<li>AYRO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AYRO#NASDAQ">AYRO</a>) stock fell 5.31% to $0.4. The company's market cap stands at $2.7 million. As per the press release, Q1 earnings came out 4 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AYRO

BGFV

LVLU

MTEN

POWW

SDHC

SHCO

XWEL

12 Consumer Discretionary Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) stock moved upwards by 39.5% to $0.38 during Tuesday's after-market session. The company's market cap stands at $55.3 million. </li>
<li>Petros Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>) stock rose 26.37% to $0.16. The company's, Q1 earnings came out 3 days ago. </li>
<li>MetaVia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTVA#NASDAQ">MTVA</a>) stock rose 15.6% to $0.81. The market value of their outstanding shares is at $8.2 million. As per the press release, Q1 earnings came out 4 days ago. </li>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock rose 9.8% to $5.61. The market value of their outstanding shares is at $510.8 million. The company's, Q2 earnings came out 3 days ago. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock rose 7.23% to $0.44. The market value of their outstanding shares is at $12.1 million. </li>
<li>VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) stock increased by 6.7% to $0.52. The market value of their outstanding shares is at $53.9 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares fell 9.0% to $5.49 during Tuesday's after-market session. The market value of their outstanding shares is at $83.5 million. </li>
<li>HeartSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) shares declined by 6.46% to $4.2. The company's market cap stands at $4.5 million. </li>
<li>OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) stock fell 6.21% to $11.18. The company's market cap stands at $206.7 million. </li>
<li>HilleVax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLVX#NASDAQ">HLVX</a>) stock declined by 5.95% to $1.9. The company's market cap stands at $95.1 million. </li>
<li>Intensity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTS#NASDAQ">INTS</a>) shares decreased by 5.94% to $0.39. The company's market cap stands at $7.1 million. </li>
<li>Xtant Medical Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/XTNT#AMEX">XTNT</a>) stock decreased by 5.77% to $0.66. The market value of their outstanding shares is at $92.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HLVX

HSCS

INTS

MTVA

ONMD

OPRX

PTPI

VNRX

XTNT

12 Health Care Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Decent Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXST#NASDAQ">DXST</a>) stock moved upwards by 8.9% to $1.35 during Tuesday's after-market session. The company's market cap stands at $21.9 million. </li>
<li>Urban-gro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) stock moved upwards by 6.58% to $0.42. The market value of their outstanding shares is at $5.2 million. </li>
<li>PS International Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) shares rose 6.28% to $0.33. The company's market cap stands at $8.0 million. </li>
<li>NeoVolta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOV#NASDAQ">NEOV</a>) shares rose 5.73% to $3.22. The market value of their outstanding shares is at $109.8 million. </li>
<li>Freightos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>) shares rose 4.93% to $2.55. The company's market cap stands at $127.6 million. The company's, Q1 earnings came out today. </li>
<li>GrafTech International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAF#NYSE">EAF</a>) stock rose 4.8% to $1.09. The company's market cap stands at $281.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Centuri Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRI#NYSE">CTRI</a>) stock fell 8.6% to $17.92 during Tuesday's after-market session. The market value of their outstanding shares is at $1.5 billion. </li>
<li>Expion360 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPON#NASDAQ">XPON</a>) stock fell 7.33% to $0.82. The market value of their outstanding shares is at $2.5 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>FBS Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBGL#NASDAQ">FBGL</a>) shares fell 7.0% to $0.65. The market value of their outstanding shares is at $8.7 million. </li>
<li>Graphjet Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>) stock decreased by 6.78% to $0.16. The company's market cap stands at $22.8 million. </li>
<li>Lakeside Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSH#NASDAQ">LSH</a>) stock declined by 5.95% to $0.95. The market value of their outstanding shares is at $7.1 million. As per the press release, Q3 earnings came out 3 days ago. </li>
<li>Samfine Creation Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFHG#NASDAQ">SFHG</a>) stock fell 5.01% to $0.87. The company's market cap stands at $17.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CRGO

CTRI

DXST

FBGL

NEOV

PSIG

SFHG

UGRO

XPON

12 Industrials Stocks Moving In Tuesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Greenidge Generation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GREE#NASDAQ">GREE</a>) stock moved upwards by 9.5% to $1.38 during Tuesday's after-market session. The market value of their outstanding shares is at $15.7 million. As per the press release, Q1 earnings came out 3 days ago. </li>
<li>PicoCELA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCLA#NASDAQ">PCLA</a>) stock increased by 8.78% to $0.52. The market value of their outstanding shares is at $16.0 million. </li>
<li>Evolv Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>) stock increased by 6.49% to $5.9. The market value of their outstanding shares is at $964.4 million. As per the news, the Q1 earnings report came out today. </li>
<li>Inuvo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/INUV#AMEX">INUV</a>) shares moved upwards by 5.38% to $0.47. The company's market cap stands at $67.9 million. </li>
<li>Keysight Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEYS#NYSE">KEYS</a>) stock increased by 5.2% to $171.27. The market value of their outstanding shares is at $29.5 billion. The company's, Q2 earnings came out today. </li>
<li>Rackspace Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXT#NASDAQ">RXT</a>) shares increased by 5.0% to $1.26. The company's market cap stands at $299.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Wolfspeed (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) shares fell 46.0% to $1.69 during Tuesday's after-market session. The company's market cap stands at $263.0 million. </li>
<li>UTime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTO#NASDAQ">WTO</a>) shares fell 14.97% to $2.0. The market value of their outstanding shares is at $51.6 million. </li>
<li>QXO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NYSE">QXO</a>) stock declined by 8.02% to $16.88. The market value of their outstanding shares is at $8.7 billion. </li>
<li>Key Tronic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTCC#NASDAQ">KTCC</a>) stock declined by 7.61% to $2.89. The market value of their outstanding shares is at $31.1 million. </li>
<li>Cipher Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIFR#NASDAQ">CIFR</a>) stock declined by 7.41% to $3.5. The market value of their outstanding shares is at $1.2 billion. </li>
<li>Thumzup Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TZUP#NASDAQ">TZUP</a>) shares fell 6.58% to $7.53. The company's market cap stands at $70.9 million. As per the news, the Q1 earnings report came out 3 days ago. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CIFR

EVLV

GREE

INUV

KEYS

KTCC

PCLA

TZUP

12 Information Technology Stocks Moving In Tuesday's After-Market Session

Garrett Motion Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTX#NASDAQ">GTX</a>)&nbsp;("Garrett" or the "Company"), a leading differentiated automotive technology provider, today announced a proposed secondary public offering of 17,000,000 shares of the Company's common stock held by certain entities managed by affiliates of Oaktree Capital Management, L.P., Centerbridge Partners, L.P. and Cyrus Capital Partners, L.P. (collectively, the "Selling Stockholders"). The underwriters will have a 30-day option to purchase at their own election up to an additional 2,550,000 shares of common stock from the Selling Stockholders. The Selling Stockholders will receive all of the net proceeds from the proposed offering. The Company is not selling any shares and will not receive any proceeds from the proposed offering.
Garrett has authorized the concurrent purchase from the underwriters of approximately 2 million shares of common stock as part of the secondary public offering (the "Repurchase"), subject to the completion of the offering, subject to a maximum aggregate repurchase amount of $25 million. The Repurchase is part of the Company's existing $250 million share repurchase program. The underwriters will not receive any compensation for the shares being repurchased by the Company pursuant to the Repurchase.

Buybacks

Garrett Motion Announces 17M Share Secondary Offering By Oaktree, Centerbridge, And Cyrus Capital And $25M Concurrent Share Repurchase Under Existing Buyback Program

Management

MTUS

Metallus Promotes Kristopher R. Westbrooks To President And COO And John M. Zaranec To CFO, Effective June 16, 2025

CXApp Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXAI#NASDAQ">CXAI</a>) released its first-quarter results after Tuesday's closing bell. Here's a look at the details<a href="https://www.benzinga.com/pressreleases/25/05/ac45529780/cxapp-inc-nasdaq-cxai-reports-strong-q125-customer-success-metrics-and-adoption-of-agentic-ai-bas"> from the report. </a>
The Details: CXApp reported quarterly losses of eight cents per share, which beat the analyst consensus estimate of losses of 24 cents and is up from losses of 34 cents from the same period last year.
Read Next: <a href="https://www.benzinga.com/news/large-cap/25/05/45524565/nvidias-1-trillion-comeback-shows-deepseek-no-longer-spooks-wall-street?utm_source=articleShare">Nvidia&#8217;s $1 Trillion Comeback Shows DeepSeek No Longer Spooks Wall Street&nbsp;</a>
For the first quarter, CXApp reported: 
<ul class="wp-block-list">
<li>ARR Expansion Growth of more than 130% and renewals for three large Fortune 500 clients</li>
<li>Subscription to One time Revenue split of 99%, up from 87% in the first quarter of 2024.</li>
<li>Gross Margin of 88%, up from 82% in the first quarter of 2024.</li>
</ul>
&#8220;The CXAI platform anchored on customer experience (CX) and artificial intelligence (AI) is the most advanced technology solution solving the biggest problems in our industry post the pandemic — the Return to Office (RTO) and Employee Engagement. The first quarter in 2025 has seen a resurgence of RTO mandates and an increased interest in Agentic AI solutions that are transformational to employee experiences,&#8221; CEO Khurram Sheikh commented.
CXAI Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, CXApp stock was down 3.60% at $1.34 after-hours on Tuesday.  
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45506863/trumps-big-beautiful-bill-advances-heres-who-wins-and-loses?utm_source=articleShare">Trump&#8217;s &#8216;Big Beautiful Bill&#8217; Advances: Here&#8217;s Who Wins And Loses&nbsp;</a></li>
</ul>
Image: Shutterstock

Earnings

CXAI

CXApp Reports Better-Than-Expected Q1 Earnings: Details

In the current market session, Caterpillar Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>) share price is at $349.50, after a 0.87% drop. Over the past month, the stock spiked by 20.03%, but over the past year, it actually decreased by 1.81%. With good short-term performance like this, and questionable long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.

<img src="https://www.benzinga.com/files/images/story/2025/1747774830_0.png" alt="Past Year Chart" />

<h3>Evaluating Caterpillar P/E in Comparison to Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Caterpillar has a lower P/E than the aggregate P/E of 51.5 of the Machinery industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1747774830_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

P/E Ratio Insights for Caterpillar

CSWC

Capital Southwest Corp Files For Common Stock Offering Of Up To $1B

Southwest Gas Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWX#NYSE">SWX</a>) ("Southwest Gas Holdings" or the "Company") today announced the commencement of an underwritten secondary public offering of Centuri Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRI#NYSE">CTRI</a>) ("Centuri") common stock (the "Offering"), pursuant to which Southwest Gas Holdings, as the selling stockholder, is offering 9,000,000 existing shares of Centuri's common stock. Southwest Gas Holdings expects to grant the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of Centuri's common stock.
In addition to the shares of Centuri's common stock sold in the Offering, Southwest Gas Holdings announced that Icahn Partners and Icahn Partners Master Fund LP, investment entities affiliated with&nbsp;Carl C. Icahn, will purchase an aggregate of&nbsp;$50 million in shares of&nbsp;Centuri's common stock from Southwest Gas Holdings in a concurrent private placement at a price per share equal to the Offering price per share. The concurrent private placement is expected to close immediately following the closing of the Offering and is subject to the satisfaction or waiver of customary closing conditions, including the completion of the Offering. The sale of these shares will not be registered under the Securities Act of 1933, as amended (the "Securities Act"). The closing of the Offering is not conditioned upon the closing of the concurrent private placement.

Southwest Gas Holdings Launches Secondary Public Offering Of 9M Centuri Shares And Announces $50M Private Placement With Icahn Affiliates At Offering Price

WIIM

D.R. Horton shares are trading higher in possible sympathy with Toll Brothers, which rose after reporting Q2 results.

I got into the investment business on a steady diet of Graham and Whitman. But that was the 1980s and early 1990s – the golden age of dealmakers and junk bonds, leveraged buyouts and greenmail. 
Long before the players became gentlemanly private equity titans and activist investors, they were raiders, vultures, and even, in one famous book about the RJR deal, barbarians.
Legendary fortunes were made, reputations created and shattered.
All of these high-return, high-flying strategies shared a common thread. Leveraged buyouts, distressed investing and risk arb were all just variations on the value investing theme.
The private equity giants of today are still doing this. Thanks to their quarterly filings, you can copy their investment approach—a strategy that has beaten the markets 4-to-1 since 2001.
Even the creation of the junk bond market was based on Michael Milken&#8217;s studies on the returns from buying undervalued lower-rated bonds, a strategy founded on basic value investing principles.
The big winners in all these strategies took value investing and added debt.
It was like adding nitro to the tank of a stock car. If you could control the vehicle at high speed through the corners, there was no race you couldn&#8217;t win.
Although the golden age of risk arb and the smaller investors&#8217; ability to compete in distressed debt are all behind us, we can still use the combination of debt and value investing to beat the index by a wide margin.
When the 13F filings come out every quarter, most of the short-attention-spans in the market today head for the same filings at the same time.
Warren, Cathie, Stanley, Tepper and Seth still get all the attention.
I may get around to those at some point, but one of the first places I turn is to the leading private equity firms.
Firms like Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>), Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) and KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) still use basic principles of value investing along with a healthy dose of debt to drive massive returns for themselves and their investors.
What most people do not realize is that these firms also have large public securities portfolios, and stealing their ideas has created some massive market-beating opportunities.
If you had bought shares of Mr. Cooper (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NASDAQ">COOP</a>) when it first appeared in KKR&#8217;s public portfolio in 2018, you could have made almost ten times your money.
Buying shares of AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) when KKR first revealed its position would have resulted in gains of almost seven times your initial cost.
DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) would have delivered gains of 3x in just a few years.
Owning the firm&#8217;s top ten holdings since 2001 would have beaten the market by a 4-to-1 margin.
I do not care what the media darling investors bought last quarter. Tell me what the profit pirates at KKR own, and I can create an opportunity to score massive gains.
The current top ten holdings for KKR are:
BrightSpring Health Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTSG#NASDAQ">BTSG</a>) provides home and community-based health services to complex patients, positioning itself in a niche with long-term demographic tailwinds. The company is newly public and pursuing scale through both organic growth and targeted acquisitions in behavioral and specialty pharmacy segments.
Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) is a global distributor of dental and medical supplies primarily serving small- and mid-sized practices. The company generates stable cash flow and has a long history of disciplined capital deployment, though growth is modest and sensitive to procedure volume trends.
BrightView (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BV#NYSE">BV</a>) is the largest commercial landscaping services provider in the U.S., with recurring maintenance revenue making up the majority of its business. Under new leadership, the firm is undergoing a restructuring push to improve margins and reduce debt after years of underperformance.
KKR Real Estate Finance Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KREF#NYSE">KREF</a>) is a commercial mortgage REIT focused on senior loans backed by institutional-grade real estate, primarily in urban markets. It offers a high dividend yield but remains exposed to office market weakness and refinancing risk in a higher-rate environment.
Madison Square Garden Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSGS#NYSE">MSGS</a>) owns marquee sports franchises, including the New York Knicks and Rangers, offering investors a rare asset-backed play on professional sports. Valuation is driven more by franchise appreciation than earnings power, making it a long-duration, event-driven asset.
Norwegian Cruise Line (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) is a leading cruise operator with a strong focus on premium and upscale offerings across its brand portfolio. The company is rebounding from pandemic-era disruptions, though it still carries significant leverage and remains sensitive to fuel and labor costs.
Bausch Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHC#NYSE">BHC</a>) is a diversified specialty pharmaceutical company with exposure to eye health, dermatology, and branded generics. However, the company is still burdened by high legacy debt. While it&#8217;s pursuing a turnaround strategy and asset divestitures, legal overhangs and weak cash flow remain headwinds.
FS KKR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSK#NYSE">FSK</a>) is one of the largest business development companies, focused on senior secured lending to middle-market companies with an emphasis on downside protection. It offers a double-digit yield and strong sponsor backing, though credit quality and NAV stability require close monitoring.
Crescent Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSGY#NYSE">CSGY</a>) is a cash-generating E&amp;P company with a private equity-backed structure and a focus on acquiring and optimizing mature, low-decline assets. The firm maintains a disciplined capital return framework and hedging strategy, making it a defensive upstream play with yield upside.
BridgeBio Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>) is a commercial-stage biopharmaceutical company developing treatments for genetic diseases and cancers with clear genetic drivers. Its lead drug, Attruby (acoramidis), approved in late 2024 for transthyretin amyloid cardiomyopathy, significantly outperformed sales expectations in its first full quarter, positioning the company as a strong competitor in the cardiomyopathy treatment market.
<h2 class="wp-block-heading">Turn Market Mayhem Into Profit Signals This Memorial Day</h2>
Get real-time portfolio alerts, daily stock ideas, and a suite of pro-grade tools — all in one elite membership. For a limited time, you can access Benzinga Edge at 60% off. Secure Your 60% Memorial Day Discount <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-memorial-day-special/?utm_campaign=mdw-sale&amp;utm_adType=sponsorad&amp;utm_ad=RD052025/?el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_medium=newsletter">HERE</a>.
Editorial content from our expert contributors is intended to be information for the general public and not individualized investment advice. Editors/contributors are presenting their individual opinions and strategies, which are neither expressly nor impliedly approved or endorsed by Benzinga.
Photo: Shutterstock

Opinion

BBIO

BTSG

COOP

CSGY

DASH

HSIC

KREF

MSGS

NCLH

The Smart Money Is Buying These 10 Stocks

Keysight Technologies shares are trading higher following better-than-expected Q2 financial results.

Press Releases

Enzolytics, Inc. Announces Letter of Intent for Exclusive Licensing Agreement for Patented Nitric Oxide Formulation

Enzolytics, Inc. Poised to Invest Alongside Sagaliam Acquisition Corp in Revolutionary Room Temperature SPAD Technology

Enzolytics, Inc. Enters Into Exclusive Worldwide License for Patented Immunotherapy Cancer Treatment

SAGALIUM RESPONDS TO COMPETITOR'S FALSE AND MISLEADING PRESS RELEASE

Enzolytics Inc. Supports Sagaliam Acquisition Corp Response to Competitors False and Misleading Press Release

Enzolytics, Inc. Enters Into Collaboration Agreement With Manufacturer Elimus Ltd.

Enzolytics, Inc. and the Bulgarian Academy of Sciences Initiate a Cooperative Program Primarily Focusing on Applied and Strategic Research in Immunology for Cancer and HIV/AIDS Applications

Final Report From the National Centre of Infectious and Parasitic Diseases Concludes Lyophilized Pepsin Significantly Reduces the Survival and Proliferation of Growth in Specific Cancer Cells

Department of Immunology, Institute of Microbiology, Bulgarian Academy of Sciences  and Enzolytics, Inc. Execute Three Year Agreement

Bulgarian Academy of Sciences Issues Report on Results of Its In Vivo Testing of IPF as an Immunomodulator

ENZC

Enzolytics

Comments

Enzolytics

Noticias

Últimas noticias sobre Enzolytics (OTC:ENZC) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL